MedTrace Logo

EFFECTS OF TRANEXAMIC ACID IN TUMESCENT SOLUTION FOR LIPOSUCTION PROCEDURES

NCT06648265 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-04-30

No results posted yet for this study

Summary

The goal of this trial is to evaluate the effect of adding Tranexamic Acid (TXA) to the tumescent solution used in arm liposuction on postoperative outcomes. Study population includes healthy volunteer adults undergoing Liposculpture procedures. The main question it aims to answer is:

1\. Does Tranexamic acid exert benefit on postoperative outcomes after liposuction? Researchers will compare TXA versus traditional tumescent solution to see if there are benefits on adding it to the tumescent solution.

Participants will undergo High Definition Liposculpture involving arms, legs and their torso. One arm will be infiltrated with traditional Klein's tumescent solution and the other one with the same one but adding Tranexamic Acid.

Conditions

  • Liposuction
  • Bruising
  • Inflammation
  • Skin Condition
  • Edema Arm
  • Ecchymosis
  • Hematoma

Interventions

DRUG

Tranexamic Acid (Topical)

Add 250 mg of TXA per liter of Klein\'s Tumescent solution for arm liposculpture

DRUG

Tumescent solution with dilute lidocaine and epinephrine

Arm infiltration with traditional Klein\'s tumescent solution

Sponsors & Collaborators

  • Total Definer Research Group

    lead OTHER

Principal Investigators

  • Mauricio E Perez Pachon, MD · Department of Plastic Surgery | Scientific Division | Total Definer

  • Alfredo E Hoyos, MD · Department of Plastic Surgery | Total Definer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2024-02-15
Completion
2024-06-13

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06648265 on ClinicalTrials.gov